{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:48:02Z","timestamp":1788994082263,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01140-0","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:46:03Z","timestamp":1779090363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Dina M.","family":"Khodeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally M.","family":"Abdelmonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komla Mawunyo","family":"Dossouvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Adawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"1140_CR1","unstructured":"Pescador Ruschel MA, De Jesus O. Migraine headache, in StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC; 2025."},{"key":"1140_CR2","doi-asserted-by":"publisher","unstructured":"Ashina M, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485\u20131495. https:\/\/doi.org\/10.1016\/s0140-6736(20)32160-7","DOI":"10.1016\/s0140-6736(20)32160-7"},{"key":"1140_CR3","doi-asserted-by":"publisher","unstructured":"Raggi A, et al. Hallmarks of primary headache: part 1 - migraine. J Headache Pain. 2024 Oct 31;25(1):189. https:\/\/doi.org\/10.1186\/s10194-024-01889-x.","DOI":"10.1186\/s10194-024-01889-x"},{"key":"1140_CR4","doi-asserted-by":"publisher","unstructured":"Gupta J, Gaurkar SS. Migraine: an underestimated neurological condition affecting billions. Cureus. 2022 Aug;14(8):e28347. https:\/\/doi.org\/10.7759\/cureus.28347","DOI":"10.7759\/cureus.28347"},{"key":"1140_CR5","doi-asserted-by":"publisher","unstructured":"Robbins MS. Diagnosis and management of headache: a review. JAMA. 2021 May 11;325(18):1874\u20131885. https:\/\/doi.org\/10.1001\/jama.2021.1640","DOI":"10.1001\/jama.2021.1640"},{"key":"1140_CR6","doi-asserted-by":"publisher","unstructured":"Sacco S, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. https:\/\/doi.org\/10.1186\/s10194-022-01502-z.","DOI":"10.1186\/s10194-022-01502-z"},{"key":"1140_CR7","doi-asserted-by":"publisher","unstructured":"Ran Y, et al. Migraine management in Chinese headache centers: a national survey and the role of quality control inspections. J Headache Pain. 2025 Nov 27;26(1):273. https:\/\/doi.org\/10.1186\/s10194-025-02224-8. (in eng).","DOI":"10.1186\/s10194-025-02224-8"},{"key":"1140_CR8","doi-asserted-by":"publisher","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020 Jul;211:107528. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","DOI":"10.1016\/j.pharmthera.2020.107528"},{"key":"1140_CR9","doi-asserted-by":"publisher","unstructured":"Younis S, Latysheva NV, Danilov AB, Ashina M. CGRP receptor antagonists (gepants). Handb Clin Neurol. 2024;199:51\u201366. https:\/\/doi.org\/10.1016\/b978-0-12-823357-3.00033-1","DOI":"10.1016\/b978-0-12-823357-3.00033-1"},{"key":"1140_CR10","doi-asserted-by":"publisher","unstructured":"Anukoolwittaya P, et al. Expert consensus on gepants for acute and preventive treatment of migraine in Thailand. J Headache Pain. 2025 Jun 2;26(1):131. https:\/\/doi.org\/10.1186\/s10194-025-02074-4.","DOI":"10.1186\/s10194-025-02074-4"},{"key":"1140_CR11","doi-asserted-by":"publisher","unstructured":"Blair HA. Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs. 2023 Mar;37(3):255\u2013265. https:\/\/doi.org\/10.1007\/s40263-023-00988-8","DOI":"10.1007\/s40263-023-00988-8"},{"key":"1140_CR12","doi-asserted-by":"publisher","unstructured":"Wang J, et al. Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study. J Headache Pain. 2025 Nov 7;26(1):242. https:\/\/doi.org\/10.1186\/s10194-025-02197-8.","DOI":"10.1186\/s10194-025-02197-8"},{"key":"1140_CR13","doi-asserted-by":"publisher","unstructured":"Negro A, Martelletti P. Rimegepant for the treatment of migraine. Drugs Today (Barc). 2020 Dec;56(12):769\u2013780. https:\/\/doi.org\/10.1358\/dot.2020.56.12.3211624","DOI":"10.1358\/dot.2020.56.12.3211624"},{"key":"1140_CR14","doi-asserted-by":"publisher","unstructured":"Iannone LF, et al. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain. 2025 Jan 6;26(1):4. https:\/\/doi.org\/10.1186\/s10194-024-01935-8.","DOI":"10.1186\/s10194-024-01935-8"},{"key":"1140_CR15","doi-asserted-by":"publisher","unstructured":"Matsumori Y, et al. Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study. J Headache Pain. 2026 Feb 27;27(1). https:\/\/doi.org\/10.1186\/s10194-026-02290-6. (in eng).","DOI":"10.1186\/s10194-026-02290-6"},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1140_CR17","doi-asserted-by":"publisher","unstructured":"Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"1140_CR18","doi-asserted-by":"publisher","unstructured":"Croop R, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x","DOI":"10.1016\/s0140-6736(19)31606-x"},{"key":"1140_CR19","doi-asserted-by":"publisher","unstructured":"Ikeda K, et al. Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: a dose-ranging, double-blind, randomized controlled trial. Headache. 2025 Jun 30. https:\/\/doi.org\/10.1111\/head.14994.","DOI":"10.1111\/head.14994"},{"key":"1140_CR20","doi-asserted-by":"publisher","unstructured":"Kitamura S, et al. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: a double-blind, randomized controlled trial. Headache. 2025 Sep;65(8):1403\u20131412. https:\/\/doi.org\/10.1111\/head.14995","DOI":"10.1111\/head.14995"},{"key":"1140_CR21","doi-asserted-by":"publisher","unstructured":"Lipton RB, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019 Jul 11;381(2):142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090.","DOI":"10.1056\/NEJMoa1811090"},{"key":"1140_CR22","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/jpr.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R. Efficacy and safety of rimegepant 75 mg oral tablet for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res. 2024;17:2431\u20132441. https:\/\/doi.org\/10.2147\/jpr.S453806.","journal-title":"J Pain Res"},{"key":"1140_CR23","doi-asserted-by":"publisher","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo-controlled, dose-ranging trial. Cephalalgia. 2014 Feb;34(2):114\u2013125. https:\/\/doi.org\/10.1177\/0333102413500727","DOI":"10.1177\/0333102413500727"},{"key":"1140_CR24","doi-asserted-by":"publisher","unstructured":"Kudrow D, Croop RS, Thiry A, Lipton RB. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache. 2025 Jun 30. https:\/\/doi.org\/10.1111\/head.15002","DOI":"10.1111\/head.15002"},{"key":"1140_CR25","doi-asserted-by":"publisher","unstructured":"Croop R, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(20)32544-7","DOI":"10.1016\/s0140-6736(20)32544-7"},{"key":"1140_CR26","doi-asserted-by":"publisher","unstructured":"Yu S, et al. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a phase 3 clinical trial. J Headache Pain. 2024 Apr 16;25(1):57. https:\/\/doi.org\/10.1186\/s10194-024-01731-4.","DOI":"10.1186\/s10194-024-01731-4"},{"key":"1140_CR27","doi-asserted-by":"publisher","unstructured":"Yang CP, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021 Oct 1;4(10):e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544","DOI":"10.1001\/jamanetworkopen.2021.28544"},{"key":"1140_CR28","doi-asserted-by":"publisher","unstructured":"Moisset X, et al. Migraine treatment: position paper of the French Headache Society. Rev Neurol (Paris). 2024 Dec;180(10):1087\u20131099. https:\/\/doi.org\/10.1016\/j.neurol.2024.09.008","DOI":"10.1016\/j.neurol.2024.09.008"},{"key":"1140_CR29","doi-asserted-by":"publisher","unstructured":"Caronna E, Starling AJ. Update on calcitonin gene-related peptide antagonism in the treatment of migraine. Neurol Clin. 2021 Feb;39(1):1\u201319. https:\/\/doi.org\/10.1016\/j.ncl.2020.09.001","DOI":"10.1016\/j.ncl.2020.09.001"},{"key":"1140_CR30","doi-asserted-by":"publisher","unstructured":"Chaudhry BA, et al. Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study. Brain Commun. 2026;8(1):fcag004. https:\/\/doi.org\/10.1093\/braincomms\/fcag004","DOI":"10.1093\/braincomms\/fcag004"},{"key":"1140_CR31","doi-asserted-by":"publisher","unstructured":"Dodick DW, et al. Ubrogepant for the Treatment of Migraine, (in eng). N Engl J Med. Dec 5 2019;381(23):2230\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813049.","DOI":"10.1056\/NEJMoa1813049"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01140-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:45:06Z","timestamp":1779720306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01140-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01140-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}